ClinicalTrials.gg
CompletedNCT04924062Updated Apr 15, 2026Results posted

Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)-China Extension Study

A Phase 3 interventional study of Pembrolizumab and Gemcitabine in Biliary Tract Carcinoma, sponsored by Merck Sharp & Dohme LLC. Completed at 22 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-15.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 10 months after the study started (first participant enrolled Jul 2020, registered Jun 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
158
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing pembrolizumab in Cholangiocarcinoma — 3 open to participants now, 5 under way, 1 of them phase 3. pembrolizumab · Cholangiocarcinoma.

Enrollment
5th of 12
158 · median 91
Started
2020
with 1 other
Phase 3
3 of 12
none open now
Registered
8th of 12
by date
Lead sponsor
3 of 12
Merck Sharp & Dohme LLC

Among the 12 studies testing pembrolizumab in Cholangiocarcinoma, this one is the 5th largest by enrollment, is one of 2 that started in 2020, is one of 3 in phase 3, and was the 8th registered.

Cholangiocarcinoma

825 studies on the registry are indexed under Cholangiocarcinoma; 288 are open to participants now.

Browse Cholangiocarcinoma studies →

Open to participants now

3 of the 12 studies testing pembrolizumab in Cholangiocarcinoma are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About pembrolizumab

pembrolizumab: first FDA approval 2014 (KEYTRUDA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 211 Cholangiocarcinoma studies recruiting now, 141 (67%) set no upper age limit and 49 (23%) stop at 75 or younger; 10 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing pembrolizumab in Cholangiocarcinoma, or all of them as a file.
02

Study summary

In this China Extension study, pembrolizumab plus gemcitabine/cisplatin will be compared with placebo plus gemcitabine/cisplatin as first-line therapy in Chinese adults with advanced and/or unresectable biliary tract carcinoma. The primary hypothesis is pembrolizumab plus gemcitabine/cisplatin is superior to placebo plus gemcitabine/cisplatin with respect to overall survival (OS).

Read the detailed description

The China extension study will include participants previously enrolled in China in the global study for MK-3475-966 (NCT04003636) plus those enrolled during the China extension enrollment period. A total of approximately 158 Chinese participants will be enrolled.

03

Conditions studied

  • Biliary Tract Carcinoma

Keywords

  • Programmed cell death 1 (PD-1)
  • Pembrolizumab
  • Cholangiocarcinoma
  • Gallbladder cancer
  • Checkpoint inhibitor
  • Immunotherapy
  • Biliary
  • Keytruda
  • Bile Duct Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has confirmed diagnosis of advanced () and/or unresectable (locally advanced) biliary tract cancer (intra-or extrahepatic cholangiocarcinoma or gallbladder cancer)
  • Has based on (RECIST 1.1), as determined by the site investigator
  • Participants with a history of or can be enrolled if they meet study criteria
  • Is able to provide sample or newly obtained core or excisional biopsy of a tumor lesion
  • Has a of greater than 3 months
  • Has adequate organ function

Exclusion criteria

Exclusion Criteria

  • Has had previous systemic therapy for advanced () or unresectable (locally advanced) biliary tract cancer (intra-or extra hepatic cholangiocarcinoma or gallbladder cancer)
  • Has ampullary cancer
  • Has small cell cancer, neuroendocrine tumors, lymphoma, sarcoma, mixed tumor histology and/or mucinous cystic neoplasms
  • Has received prior therapy with an anti-programmed cell death 1 (), anti- programmed cell death ligand 1 or 2 (anti-PD-L1, anti-PD-L2) agent or with an agent directed to another stimulatory or coinhibitory T-cell receptor (e.g., cytotoxic T-lymphocyte-associated protein 4 [CTLA-4], OX-40, CD137)
  • Has a known history of, or any evidence of, central nervous system (CNS) metastases and/or carcinomatous meningitis, as assessed by local site investigator
  • Has had an allogenic tissue/solid organ transplant
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
158 participants (actual)

Study arms

  • Experimental
    Arm A: Pembrolizumab + Chemotherapy

    Participants receive pembrolizumab, 200 mg intravenous (IV) infusion, every 3 weeks (Q3W), Day 1 of each 3-week cycle for up to 35 cycles PLUS gemcitabine, 1000 mg/m\^2, IV infusion Q3W, Day 1 and Day 8 of each 3-week cycle until progressive disease or unacceptable toxicity PLUS cisplatin, 25 mg/m\^2 IV infusion, Q3W, Day 1 and Day 8 of each 3-week cycle for up to 8 cycles. Eligible participants who stop the initial course of pembrolizumab with stable disease (SD) or better but progress after discontinuation will initiate a second course of pembrolizumab 200 mg IV Q3W, Day 1 of each 3-week cycle for up to 17 cycles. Treatment with gemcitabine can be stopped at any time in first or second course due to toxicity or disease progression.

    Biological: Pembrolizumab · Drug: Gemcitabine · Drug: Cisplatin

  • Placebo comparator
    Arm B: Placebo + Chemotherapy

    Participants receive placebo to pembrolizumab, 200 mg IV infusion, every 3 weeks (Q3W), Day 1 of each 3-week cycle for up to 35 cycles PLUS gemcitabine, 1000 mg/m\^2 IV infusion, Q3W, Day 1 and Day 8 of each 3-week cycle until progressive disease or unacceptable toxicity PLUS cisplatin, 25 mg/m\^2 IV infusion, Q3W, Day 1 and Day 8 of each 3-week cycle for up to 8 cycles.

    Drug: Gemcitabine · Drug: Cisplatin · Drug: Placebo

Interventions

  • BiologicalPembrolizumab

    Pembrolizumab by intravenous (IV) infusion

    Also known as: MK-3475

  • Gemcitabine by IV infusion

    Also known as: Gemzar

  • Cisplatin by IV infusion

    Also known as: Platinol®, Platinol®-AQ

  • DrugPlacebo

    Placebo to pembrolizumab by IV infusion

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    Overall survival was defined as the time from randomization to death due to any cause. Per protocol the final reported outcome for OS did not include any sensitivity or supportive analysis.

    Time frame: Up to approximately 29 months

Secondary outcomes

  1. Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by BICR

    PFS was defined as the time from randomization to the first documented disease progression (PD) or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. PFS as assessed by BICR per RECIST 1.1 was presented.

    Time frame: Up to approximately 29 months

  2. Objective Response Rate (ORR) Per RECIST 1.1 as Assessed by BICR

    ORR was defined as the percentage of participants who had a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: a ≥30% decrease in the sum of diameters \[SOD\] of target lesions) as assessed by BICR per RECIST 1.1, which was adjusted for this study to allow a maximum of 10 target lesions in total and 5 per organ.

    Time frame: Up to approximately 29 months

  3. Duration of Response (DOR) Per RECIST 1.1 as Assessed by BICR

    For participants who demonstrated a confirmed CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR was defined as the time from first documented evidence of a CR or PR until PD or death. DOR for participants who had not progressed or died at the time of analysis was to be censored at the date of their last tumor assessment. Per RECIST 1.1, PD was defined as at least a 20% increase in the sum of diameters of target lesions as well as an absolute increase of at least a 5 mm in the sum of diameters. The appearance of one or more new lesions was also considered PD. DOR assessments were based on BICR with confirmation. The DOR as assessed using RECIST 1.1 for all participants who experienced a confirmed CR or PR was presented.

    Time frame: Up to approximately 29 months

  4. Number of Participants Who Experienced One or More Adverse Events (AEs)

    An adverse event (AE) was defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it was considered related to the medical treatment or procedure, that occurred during the course of the study. Number of participants who experienced one or more AEs was reported.

    Time frame: Up to approximately 29 months

  5. Number of Participants Who Discontinued Study Intervention Due to an AE

    An AE was defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it was considered related to the medical treatment or procedure, that occurred during the course of the study. Number of participants who discontinued study intervention (includes any study medication given during the study) due to an AE were reported.

    Time frame: Up to approximately 29 months

07

Results

Posted Dec 26, 2023

Participant flow

Per protocol, response or progression during the second course treatment was not counted towards efficacy outcome measures, and adverse events during the second course treatment were not counted towards safety outcome measures.

Participant flow — Overall Study
MilestoneArm A: Pembrolizumab + ChemotherapyArm B: Placebo + Chemotherapy
Started7583
Treated7482
Participants who received second course of pembrolizumab10
Completed00
Not completed7583
Withdrew: Death6577
Withdrew: Sponsor decision106

Outcome measures

PrimaryOverall Survival (OS)

Overall survival was defined as the time from randomization to death due to any cause. Per protocol the final reported outcome for OS did not include any sensitivity or supportive analysis.

Time frame:
Up to approximately 29 months
Reported as:
Median · Months
Overall Survival (OS)
MonthsArm A: Pembrolizumab + ChemotherapyArm B: Placebo + Chemotherapy
Overall Survival (OS)14.1 (10.4 to 17.7)9.9 (8.6 to 13.0)
Statistical analysis
  • Arm A: Pembrolizumab + Chemotherapy vs Arm B: Placebo + Chemotherapy · Hazard ratio (hr): 0.74 · 95% CI 0.51 to 1.08Hazard Ratio (HR) and associated 95% confidence interval (CI) was calculated using Cox regression model with Efron's method of tie handling with treatment as a covariate.
SecondaryProgression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by BICR

PFS was defined as the time from randomization to the first documented disease progression (PD) or death due to any cause, whichever occurred first. Per RECIST 1.1, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. PFS as assessed by BICR per RECIST 1.1 was presented.

Time frame:
Up to approximately 29 months
Reported as:
Median · Months
Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by BICR
MonthsArm A: Pembrolizumab + ChemotherapyArm B: Placebo + Chemotherapy
Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by BICR5.6 (3.2 to 7.4)5.7 (4.4 to 6.9)
Statistical analysis
  • Arm A: Pembrolizumab + Chemotherapy vs Arm B: Placebo + Chemotherapy · Hazard ratio (hr): 0.83 · 95% CI 0.58 to 1.19HR and associated 95% CI were calculated using Cox regression model with Efron's method of tie handling with treatment as a covariate.
SecondaryObjective Response Rate (ORR) Per RECIST 1.1 as Assessed by BICR

ORR was defined as the percentage of participants who had a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: a ≥30% decrease in the sum of diameters \[SOD\] of target lesions) as assessed by BICR per RECIST 1.1, which was adjusted for this study to allow a maximum of 10 target lesions in total and 5 per organ.

Time frame:
Up to approximately 29 months
Reported as:
Number · Percentage of participants
Objective Response Rate (ORR) Per RECIST 1.1 as Assessed by BICR
Percentage of participantsArm A: Pembrolizumab + ChemotherapyArm B: Placebo + Chemotherapy
Objective Response Rate (ORR) Per RECIST 1.1 as Assessed by BICR36.0 (25.2 to 47.9)28.9 (19.5 to 39.9)
Statistical analysis
  • Arm A: Pembrolizumab + Chemotherapy vs Arm B: Placebo + Chemotherapy · Difference in percentage: 7.1 · 95% CI -7.5 to 21.6Difference in percentage was calculated using Miettinen \& Nurminen method. Difference in percentage=Arm A minus Arm B
SecondaryDuration of Response (DOR) Per RECIST 1.1 as Assessed by BICR

For participants who demonstrated a confirmed CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR was defined as the time from first documented evidence of a CR or PR until PD or death. DOR for participants who had not progressed or died at the time of analysis was to be censored at the date of their last tumor assessment. Per RECIST 1.1, PD was defined as at least a 20% increase in the sum of diameters of target lesions as well as an absolute increase of at least a 5 mm in the sum of diameters. The appearance of one or more new lesions was also considered PD. DOR assessments were based on BICR with confirmation. The DOR as assessed using RECIST 1.1 for all participants who experienced a confirmed CR or PR was presented.

Time frame:
Up to approximately 29 months
Reported as:
Median · Months
Duration of Response (DOR) Per RECIST 1.1 as Assessed by BICR
MonthsArm A: Pembrolizumab + ChemotherapyArm B: Placebo + Chemotherapy
Duration of Response (DOR) Per RECIST 1.1 as Assessed by BICR10.2 (5.4 to NA)5.7 (4.2 to 14.0)
SecondaryNumber of Participants Who Experienced One or More Adverse Events (AEs)

An adverse event (AE) was defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it was considered related to the medical treatment or procedure, that occurred during the course of the study. Number of participants who experienced one or more AEs was reported.

Time frame:
Up to approximately 29 months
Reported as:
Count of participants · Participants
Number of Participants Who Experienced One or More Adverse Events (AEs)
ParticipantsArm A: Pembrolizumab + ChemotherapyArm B: Placebo + Chemotherapy
Number of Participants Who Experienced One or More Adverse Events (AEs)7382
SecondaryNumber of Participants Who Discontinued Study Intervention Due to an AE

An AE was defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it was considered related to the medical treatment or procedure, that occurred during the course of the study. Number of participants who discontinued study intervention (includes any study medication given during the study) due to an AE were reported.

Time frame:
Up to approximately 29 months
Reported as:
Count of participants · Participants
Number of Participants Who Discontinued Study Intervention Due to an AE
ParticipantsArm A: Pembrolizumab + ChemotherapyArm B: Placebo + Chemotherapy
Number of Participants Who Discontinued Study Intervention Due to an AE1814

Adverse events

Collected over Up to approximately 56 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
First Course: Arm A: Pembrolizumab + Chemotherapy65/75 (86.7%)29/74 (39.2%)73/74 (98.6%)
First Course: Arm B: Placebo + Chemotherapy77/83 (92.8%)29/82 (35.4%)82/82 (100%)
Second Course: Arm A: Pembrolizumab + Chemotherapy0/1 (0%)0/1 (0%)1/1 (100%)
Most frequent serious events
Showing 10 of 53
Most frequent serious events
EventFirst Course: Arm A: Pembrolizumab + ChemotherapyFirst Course: Arm B: Placebo + ChemotherapySecond Course: Arm A: Pembrolizumab + Chemotherapy
Platelet count decreasedInvestigations9/747/820/1
AnaemiaBlood and lymphatic system disorders5/743/820/1
Neutrophil count decreasedInvestigations5/742/820/1
Jaundice cholestaticHepatobiliary disorders1/745/820/1
Biliary tract infectionInfections and infestations4/744/820/1
White blood cell count decreasedInvestigations3/743/820/1
MyelosuppressionBlood and lymphatic system disorders2/741/820/1
Febrile infectionInfections and infestations2/741/820/1
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders2/740/820/1
MyocarditisCardiac disorders1/742/820/1
Most frequent other events
Showing 10 of 59
Most frequent other events
EventFirst Course: Arm A: Pembrolizumab + ChemotherapyFirst Course: Arm B: Placebo + ChemotherapySecond Course: Arm A: Pembrolizumab + Chemotherapy
Aspartate aminotransferase increasedInvestigations19/7430/821/1
AnaemiaBlood and lymphatic system disorders59/7465/820/1
White blood cell count decreasedInvestigations58/7462/820/1
Neutrophil count decreasedInvestigations55/7458/820/1
Platelet count decreasedInvestigations47/7446/820/1
NauseaGastrointestinal disorders38/7435/820/1
VomitingGastrointestinal disorders31/7437/820/1
Alanine aminotransferase increasedInvestigations16/7428/820/1
Decreased appetiteMetabolism and nutrition disorders20/7428/820/1
ConstipationGastrointestinal disorders15/7420/820/1

Baseline characteristics

All Chinese participants who were randomized to the global study (NCT04003636) or to the extension portion.

Age, Continuous
Age, Continuous(Years)Arm A: Pembrolizumab + ChemotherapyArm B: Placebo + ChemotherapyTotal
Mean59.5 ± 8.358.6 ± 9.559.0 ± 8.9
Sex: Female, Male
Sex: Female, Male(Participants)Arm A: Pembrolizumab + ChemotherapyArm B: Placebo + ChemotherapyTotal
Female393675
Male364783
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm A: Pembrolizumab + ChemotherapyArm B: Placebo + ChemotherapyTotal
Hispanic or Latino000
Not Hispanic or Latino7583158
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm A: Pembrolizumab + ChemotherapyArm B: Placebo + ChemotherapyTotal
American Indian or Alaska Native000
Asian7583158
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
Geographic Region
Geographic Region(Participants)Arm A: Pembrolizumab + ChemotherapyArm B: Placebo + ChemotherapyTotal
Asia7583158
Disease Status
Disease Status(Participants)Arm A: Pembrolizumab + ChemotherapyArm B: Placebo + ChemotherapyTotal
Locally Advanced121426
Metastatic6369132
Site of Origin
Site of Origin(Participants)Arm A: Pembrolizumab + ChemotherapyArm B: Placebo + ChemotherapyTotal
Gallbladder191231
Intrahepatic4560105
Extrahepatic111122
08

Study locations

22 sites
  • Anhui Provincial Hospital ( Site 0140)
    Hefei, Anhui 230001, China
  • Beijing Cancer Hospital ( Site 0138)
    Beijing, Beijing Municipality 100036, China
  • Peking Union Medical College Hospital ( Site 0150)
    Beijing, Beijing Municipality 100730, China
  • First Affiliated Hospital of The Third Military Medical University ( Site 0130)
    Chongqing, Chongqing Municipality 400038, China
  • Fujian Provincial Cancer Hospital ( Site 0154)
    Fuzhou, Fujian 350014, China
  • 900 Hospital of the Joint ( Site 0137)
    Fuzhou, Fujian 350025, China
  • Guangdong Provincial People s Hospital ( Site 0161)
    Guangzhou, Guangdong 510080, China
  • Harbin Medical University Cancer Hospital ( Site 0133)
    Harbin, Heilongjiang 610000, China
  • Hunan Provincial People Hospital ( Site 0142)
    Changsha, Hunan 410005, China
  • Hunan Cancer Hospital ( Site 0132)
    Changsha, Hunan 410013, China
  • The Third Xiangya Hospital of Central South University ( Site 0157)
    Changsha, Hunan 410013, China
  • The 81st Hospital of PLA ( Site 0128)
    Nanjing, Jiangsu 210031, China
  • The First Hospital of Jilin University ( Site 0131)
    Changchun, Jilin 130021, China
  • Zhongshan Hospital Fudan University ( Site 0129)
    Shanghai, Shanghai Municipality 200032, China
  • Renji Hospital Shanghai Jiaotong University School of Medicine ( Site 0158)
    Shanghai, Shanghai Municipality 200127, China
  • Fudan University Shanghai Cancer Center ( Site 0160)
    Shanghai, Shanghai Municipality 201315, China
  • Tangdu Hospital ( Site 0146)
    Xi’an, Shanxi 710038, China
  • The First Affiliated Hospital of Xi an Jiaotong University ( Site 0145)
    Xi’an, Shanxi 710048, China
  • West China Hospital of Sichuan University ( Site 0147)
    Chengdu, Sichuan 610041, China
  • Tianjin Medical University Cancer Institute & Hospital ( Site 0155)
    Tianjin, Tianjin Municipality 300060, China
  • The First Affiliated Hospital Zhejiang University ( Site 0136)
    Hangzhou, Zhejiang 310003, China
  • Zhejiang Cancer Hospital ( Site 0134)
    Hangzhou, Zhejiang 310022, China
09

References and documents

Publications

  • Ren Z, Liang T, Gu S, Gou H, Peng C, Pan Y, Song T, Su H, Cao K, Liang H, Ying J, Geng Z, Yu W, Zhao H, Bai Y, Hao C, Mao Y, Li W, Wang L, Li D, Wang W, Li N, Malhotra U, Qin S. First-Line Pembrolizumab Plus Chemotherapy for Advanced Biliary Tract Cancer: China Subgroup Analysis of the Randomized Phase 3 KEYNOTE-966 Study. Adv Ther. 2026 May 23. doi: 10.1007/s12325-026-03578-4. Online ahead of print. PubMed 42176183 ↗
  • Yoo C, Ueno M, Klumpen HJ, Kelley RK, Vogel A, Furuse J, Ren Z, Yau T, Chan SL, Ozaka M, Oh SC, Gu S, Park JO, Valle JW, Edeline J, Kim JG, Kamble S, Norquist JM, Yu L, Malhotra U, Finn RS. Health-related quality of life in participants with advanced biliary tract cancer from the randomized phase III KEYNOTE-966 study. J Hepatol. 2025 Sep;83(3):692-700. doi: 10.1016/j.jhep.2025.03.019. Epub 2025 Mar 27. PubMed 40154623 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2020 to primary completion in Dec 2022, 29 months.

Results were first posted in Dec 2023, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2021
First posted
Jun 11, 2021
StartActual
Jul 10, 2020
Primary completionActual
Dec 15, 2022
CompletionActual
Mar 25, 2025
Results first posted
Dec 26, 2023
Last update
Apr 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04924062
Responsible party
Sponsor
First posted
Jun 11, 2021
Start date
Jul 10, 2020
Primary completion
Dec 15, 2022
Completion
Mar 25, 2025
Results posted
Dec 26, 2023
Last update
Apr 15, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pembrolizumab

Start the discussion